Is Liraglutide FDA-Approved for Weight Loss?

Yes, liraglutide has an FDA-approved role in chronic weight management, but the details matter.

Liraglutide is the active ingredient in more than one product. Some liraglutide products have been approved for type 2 diabetes care. Saxenda, a liraglutide 3 mg injection, was approved for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition. It was later approved for certain adolescents with obesity. In 2025, the first generic version referencing Saxenda was approved and launched.

That is why the phrase "liraglutide for weight loss" needs context. You want to know the product, indication, dose, and whether it is FDA-approved or compounded.

Why indication matters

An FDA-approved medication has an approved label. That label describes the use, population, dosing approach, safety warnings, contraindications, and other important information.

For weight management, liraglutide is intended to be used with a reduced-calorie diet and increased physical activity. It is not a replacement for nutrition, movement, sleep, follow-up care, or medical judgment.

It is also not appropriate for everyone. A clinician needs to review your history before deciding whether to prescribe it.

What generic Saxenda means

Saxenda is the brand-name liraglutide product associated with chronic weight management. A generic version means an FDA-approved generic that references that brand product.

For patients, the generic pathway can be meaningful because FDA-approved generic drugs must meet quality and performance standards. They are not the same category as compounded medications, which are not FDA-approved before marketing.

What about generic Victoza?

Victoza is also liraglutide, but it is associated with type 2 diabetes care and uses different dosing. Generic versions referencing Victoza have also been approved.

This is why you should avoid thinking of "liraglutide" as one generic online product. The clinical context matters. Your clinician and dispensing pharmacy should be able to tell you exactly what is being prescribed and why.

Who may be considered

Many weight-management medication guidelines use body mass index and weight-related health conditions as part of the decision. For adults, health professionals may consider prescription weight-management medication for people with a BMI of 30 or greater, or a BMI of 27 or greater with weight-related health problems such as high blood pressure or type 2 diabetes.

Those thresholds are not an automatic prescription. They are a starting point for clinical evaluation.

The ClearDay difference

ClearDay's offer is built for people who want the conversation without the fog: a $49 telehealth visit with a licensed U.S. clinician to discuss FDA-approved generic liraglutide. If prescribed, medication is dispensed by a licensed pharmacy and priced separately.

ClearDay does not use compounded GLP-1 medication.

That distinction is especially important for patients who are comparing online offers that sound similar but may not be using FDA-approved medication.

Sources

• FDA: Saxenda approval for patients aged 12 and older - https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older
• FDA: 2026 Saxenda prescribing information - https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s025lbl.pdf
• Teva: Generic Saxenda approval and launch - https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx
• NIDDK: Prescription medications for overweight and obesity - https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

This article is for general information only and is not medical advice. A licensed clinician must determine whether any prescription medication is appropriate.